Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

About this update from Nexentis Technologies Inc.

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. ("Solterra") and the other lenders, for its Melz solar PV project in Germany. The Addendum follows a share purchase agreement under which Solterra and its assets are being sold to Sunflower Sustainable Investments Ltd. As a result, Solterra is making early partial repayments of the loan. The Addendum, executed together with the other lenders, includes an early partial loan repayment and reduction of profit rights. The transaction reflects a total project valuation of $14.5 million, representing a significant premium to the Company's initial investment. The Company believes that this valuation demonstrates the substantial value created in the Melz project to date. The Addendum provides immediate liquidity while preserving meaningful upside potential through the remaining profit rights, with an option for a full exit based on an independent valuation upon achievement of Ready-to-Build (RTB) status. The Melz project (approx. 111-115 MWp) continues to advance in its development phase. In connection with the transaction, the group of lenders, in which Nexentis holds the majority share, provided a total commitment of approximately $2.95 million (of which Nexentis accounts for approximately $2.18 million) to bring the 115 MWp Melz project to RTB stage. Under the Addendum, Nexentis will receive an early repayment of approximately $147,000 (including accrued interest) on its portion of the loan, plus $98,000 for the sale of 10% of its profit rights (representing 2.5% of the project's profits)) and an additional $22,000 as an option fee for the right to purchase the remaining profit rights at RTB based on an independent Big 4 valuation. The transaction reflects a total project valuation of $14.5 million ($120,000 per MW), representing a significant premium to the Company's initial investment. About Nexentis Technologies Inc. Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer and inflammatory metabo...

View stock analysis, news, and events for Nexentis Technologies Inc.